Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low ‐risk myelodysplastic syndrome. Is it feasible?

Conclusions: Prevention of specific technical pitfalls is mandatory to reach a good reproducibility of CD34+ cell count among centers. These recommendations set the basis for laboratory standardization and enable the use of CD34+ cell enumeration as additional information in low‐risk MDS patients. This article is protected by copyright. All rights reserved.
Source: Cytometry Part B: Clinical Cytometry - Category: Molecular Biology Authors: Tags: Original Article Source Type: research